OTLK's LYTENAVA wins FDA approval as first ophthalmic bevacizumab for wet AMD, targeting $8.5 billion retina market
$8.5 billion is the estimated annual size of the U.S. anti-VEGF retina market that Outlook Therapeutics, Inc. (Nasdaq: OTLK) can now address commercially. The FDA approved LYTENAVA (bevacizumab-vikg) on July 24, 2026, for neovascular…
By Warren Ashby·Jul 25, 2026·1 min read·markets·OTLK
Source: sec.gov
© 2026 NewsMeter
MarketsAug 23, 2026
Equal-weight S&P 500's flagship trade crosses $100 billion as the strategy leads the 2026 market
1 min
Markets · MUAug 20, 2026
Micron CEO challenges memory bear case in Jim Cramer interview
1 min
Markets · GOOGLAug 15, 2026
$17 billion Alphabet buy lifts Google's parent to third-largest Berkshire holding
1 min